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Abstract: Curcumin is a compound with anti-tumor effects in a tolerable dose. A recent paper by Rowe et al described that curcumin 
induced DNA damage in triple negative breast cancer cells and regulated BRCA1 protein expression and modification.1 Related research 
and potential use of curcumin will be discussed in this article.
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Curcumin (diferuloylmethane), a low-molecular-weight 
polyphenol derived from the rhizome Curcuma longa, 
is  an  active  ingredient  in  the  spice  turmeric.2 The 
compound is considered generally safe and studies in 
animals and humans have shown it has antineoplastic 
activity in a well tolerable dose.3 Curcumin has anti-
proliferative activity and inhibits tumor initiation in a 
variety of tumor models. Although the precise mech-
anism of the anti-tumor activity of curcumin remains 
elusive, several possible mechanisms have been pro-
posed, including p53-dependent apoptosis induction, 
up-regulation  of  carcinogen-detoxifying  enzymes, 
such as glutathione S-transferases, antioxidation, and 
suppression of cyclooxygenase.3
Lu et al recently discovered that curcumin induced 
DNA damage in a mouse-rat hybrid retina ganglion 
cell line.4 The real time PCR analysis showed that 
curcumin decreased expression levels of DNA dam-
age response genes, including ATM, ATR, BRCA1, 
14-3-3σ,  DNA-PK  and  MGMT.  Therefore,  reduc-
tion of DNA damage response may be the reason for 
curcumin-induced  growth  inhibition.4  The  findings 
by Rowe et al further demonstrated that regulation 
of BRCA1 protein might mediate of the anti-tumor 
reponse of curcumin.1
The  FA/BRCA  pathway  regulates  the  cellular 
response to DNA damage response.5,6 The pathway is 
governed by the coordinate activity of several FA pro-
teins. In response to various DNA damage, a protein 
complex composed of at least eight FA proteins (A, 
B, C, E, F, G, L, M) monoubiquitinates the FANCD2 
protein,7 which is subsequently targeted to chroma-
tin and interacts with the FANCD1/BRCA2 protein. 
This interaction seems to be required for homologous 
recombination repair and cross-link repair. Curcumin 
was identified as an inhibitor of FA/BRCA pathway 
in a chemical screen.3 It inhibits the monoubiquitina-
tion of the FANCD2 protein and sensitizes ovarian 
and breast tumor cell lines to cisplatin through apop-
tosis.3 However, the whole picture of curcumin puzzle 
hasn’t been solved. Rowe et al showed that BRCA1 
could be a target of curcumin when it’s used to treat 
breast  cancer.1  Curcumin  induced  DNA  damage 
was  associated  with  phosphorylation,  increased 
expression, and cytoplasmic retention of the BRCA1 
protein.1  In  addition,  curcumin  promotes  apopto-
sis  and  prevents  anchorage-independent  growth 
and migration of triple negative breast cancer cells. 
Interestingly,  apoptosis  and  BRCA1  modulation 
were  not  observed  in  non-transformed  mammary 
epithelial cells,1 suggesting some breast cancer cells 
have intrinsic defects that make them more sensitive 
to curcumin. This study indicates that curcumin may 
be of therapeutic use in the context of triple negative 
breast cancer.
As cancer formation involves more than just one 
signaling pathway dysregulation, targeting multiple 
pathways is now more preferred. To this end, cur-
cumin may be useful as a component of combina-
tional therapy for human cancers. Previous studies 
have shown that curcumin could enhance toxicity 
of  cyclophosphamide  (CTX)  on  a  drug-resistant 
human lymphoma cell line HT/CTX through inhibi-
tion of FA/BRCA pathway,8 while the curcumin or 
CTX alone did not show cytotoxic effect and had 
no inhibition of FA/BRCA pahtway. It is concluded 
that  combination  of  curcumin  and  CTX  produces 
synergistic effects and reverses multiple drug resis-
tance of HT/CTX cells effectively. The prevention 
of cells from entering the next cell cycle and down-
regulation of FANCD2 protein monoubiquitination 
may also be involved in the anti-tumor mechanism 
of  curcumin.8  Synergistic  proliferation  inhibition 
also occurred when curcumin is combined with FDA 
approved drugs like cisplatin, 5-fluorouracil (5-FU) 
or  celecoxib,  to  treat  a  variety  of  human  cancer 
cells.3,9,10
In a word, future combinational therapy develop-
ment  with  curcumin  may  provide  another  remedy 
for cancer patients. The detailed mechanistic studies 
may further shed light on novel and selective cancer 
therapies.
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